vimarsana.com

குழு ஆஃப் தி ஐரோப்பிய மேற்பார்வை அதிகாரிகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Report by the Joint Committee of the European Supervisory Authorities on the EU Securitisation Regulation | Mayer Brown - Retained Interest

Brussels Regulatory Brief: February 2021 | K&L Gates LLP

ANTITRUST AND COMPETITION The European Commission Accepts Commitments from a Pharma Company to Stop Its Excessive Prices On 15 May 2017, the European Commission (Commission) announced that it had opened formal proceedings to investigate whether a pharma company abused its dominant position by charging excessive prices for certain off-patent cancer medicines, in breach of EU antitrust rules. The Commission found that the pharma company has consistently earned very high profits from its sale of these cancer medicines in Europe, both in absolute terms and when compared with the profit levels of similar companies in the industry. In fact, the company’s prices exceeded its relevant costs by almost 300 percent on average without the Commission’s investigation revealing any justifications for the company’s high-profit levels.

Brussels Regulatory Brief: February 2021

Brussels Regulatory Brief: February 2021 Friday, March 12, 2021 The European Commission Accepts Commitments from a Pharma Company to Stop Its Excessive Prices On 15 May 2017, the European Commission (Commission) announced that it had opened formal proceedings to investigate whether a pharma company abused its dominant position by charging excessive prices for certain off-patent cancer medicines, in breach of EU antitrust rules. The Commission found that the pharma company has consistently earned very high profits from its sale of these cancer medicines in Europe, both in absolute terms and when compared with the profit levels of similar companies in the industry. In fact, the company’s prices exceeded its relevant costs by almost 300 percent on average without the Commission’s investigation revealing any justifications for the company’s high-profit levels.

Sustainable Finance Disclosure Regulation (SFDR): What To Expect | Morrison & Foerster LLP

Sustainable Finance Series – The Company s Perspective Based on research provided by ECOFACT As recently confirmed, the EU Sustainable Finance Disclosure Regulation (SFDR), becomes effective on 10 March 2021. The SFDR imposes sustainability-related disclosure requirements on financial services institutions such as banks, insurance companies, pension funds, and investment firms.[1] However, its implications go beyond the financial sector. This summary discusses how the SFDR will impact the real economy. KEY TAKEAWAYS The SFDR is expected to further shift market appetite towards sustainability-minded companies in their capacities as investees, borrowers, and issuers. The application of the SFDR will influence businesses’ capital-raising activities. Companies that are prepared and aligned with the SFDR’s requirements will have a competitive advantage in the corporate finance market.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.